Некоторые аспекты гемостазиологии в периэндоскопическом периоде

1. Федеральная служба государственной статистики Естественное движение населения Российской Федерации -2012 г. http ://www.gks.ru/bgd/regl/b12_106/Main.htm.

2. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society et al: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Europace. 2006;8:651-745.

3. Anderson M.A. Ben-Menachem T. Ian.Gan S Management of antithrombotic agents for endoscopic procedures Gatroint. Endos.Vol. 70, No. 6 : 2009 P. 1060-70.

4. Anderson M.A. Ben-Menachem T. Ian.Gan S Management of antithrombotic agents for endoscopic procedures Gatroint. Endos.Vol. 70, No. 6 : 2009 P. 1060-70.

5. Aster R.H. Pooling of platelets in the spleen: role in the pathogenesis of" hypersplenic”thrombocytopenia. J Clin Invest 1966;45(5):645-57.

6. Bassand J.P, Hamm C.W, Ardissino D et al. Guidelines forthediagnosisandtreatmentof non-ST-segment elevationacute coronarysyndromes. Eur Heart J 2007;28:1598-1660.

7. Bhatt D.L, Scheiman J, Abraham N.S et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.

8. Blacker D.J, Wijdicks E.F, McClelland R.L. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61:964-968.

9. Blanchard R.A, Furie B.C, Jorgensen M, et al. Acquired vitamin К-dependent carboxylation deficiency in liver disease. N Engl J Med 1981 ;305(5):242-8.

10. Boks A.L, Brommer E.J, Schalm S.W, et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986;6(1):79-86.

11. Bonaventura K, Sonntag S, Kleber FXAntiplatelettherapy in the era of percutaneous coronary intervention with drug-eluting balloons. Eurolntervention. 2011;7 Suppl K:K106-11.

12. Boustiere С Veitch A.,. Vanbiervliet G etal. Endoscopy and antiplateletagents European Society of Gastrointestinal Endoscopy (ESGE) Guideline: Endoscopy 2011 ;43:445-458.

13. Bux J, Sachs U.J. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007;136(6):788-99.

14. Byrne R.A, Neumann F.J, Mehilli J etal. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial Lancet. 2012:30. pii: S0140-6736(12)61964-3.

15. Caldwell S.H, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasisin liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44(4): 1039-46.

16. Caturelli E, Squillante M.M, Andriulli A, et al. Fine-needle liver biopsy in patients with severely impaired coagulation. Liver 1993; 13(5):270-3.

17. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirinversus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.Lancet. 2006:367(9526): 1903-1912.

18. Dillon J.F, Simpson K.J, Hayes P.C. Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994;9(3):269-71.

19. Drepper M.D, Spahr L, Frossard J.L. Clopidogrel and proton pump inhibitors-where do we stand in 2012? World J Gastroenterol. 2012; 18( 18):2161-71.

20. Eisen G.M, Baron T.H, Dominitz J.A, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002;55:775-779.

21. Epple C., Steiner Th. Therapie von Blutungskopliatioen bei Anikoagulanentherapie. Artzneimitteltherapie 2012; 30:338-48.

22. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981 ;26(5):388-93.

23. Faxon D.P, Lawler E, Young M, et al. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv. 2012 Jun;5(3):372-80.

24. Firdman R.J. New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis. 2010 (2010), Article ID 280731, 9 pages.

25. Friedland S, Sedehi D, Soetikno R. Colonoscopic polypectomy in anticoagulated patients. World J Gastroenterol. 2009 :28; 15( 16): 1973-6.

26. Gage B.F, Waterman A.D, Shannon W, et alValidation of clinical classification schemes for predicting stroke: Results from the national registry of atrialfibrillation. JAMA. 2001 ;285(22):2864-2870.

27. Gerson L.B, Gage B.F, Owens D.K, etal. Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol 2000;95:1717-24.

28. Goel A, Barnes C.J, Osman H, Verma A. National survey of anticoagulation policy in endoscopy. Eur J Gastroenterol Hepatol. 2007;19:51-56.

29. Goulis J, Chau T.N, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44(5):754-8.

30. Greinacher A., Kiefel V, Klter H, et.al Thrombozytentransfusion. Leitlinie.DGHO Deutsche Gesellschaft fu r H matologie und Onkologie e.V. 2011. S1-43 www.dgho-onkopedia.de

31. Hart R.G,Pearce L.A,Aguilar M.I.Meta-analysis:Antithrombotictherapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.

32. Hittelet A, Devi re J. Management of anticoagulants before and after endoscopy. Can J Gastroenterol. 2003;17:329-332.

33. Hoffmeister H.M. Bode С. Darius H. et al., •. Silber S Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Positionspapier Kardiologe 20104:365-374.

34. Hoffmeister H.M. Bode C. Darius H.- et.al Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Positionspapier Kardiologe 2010- 4:365-374.

35. Hollis R.H, Graham L.A, Richman J.S et al. Adverse cardiac events in patients with coronary stents undergoing noncardiac surgery: a systematic review. Am J Surg. 2012;204(4):494-501.

36. Htun W.W, Steinhubl S.R. Expert Opin Pharmacother. 2013; 14(2):237-45.

37. Hugenholtz G.G.C, Porte R.J., Lisman T. The Platelet andPlatelet Function Testing in Liver Disease. Clin Liver Dis 2009; 13:11 -20.

38. Hui A.J.Wong R.M.Ching J Yetal Riskof colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases.,Gastrointest Endosc. 2004; 59(1):44-8.

39. Kiefel V., Greinacher A Differenzialdiagnose und Differenzial-therapie der Thrombozytopenie Der Internist 2010 Vol. 51 (11), pp 1397-1410.

40. Kim B.K,Hong M.K,Shin D.H,etal Anewstrategyfordiscontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012 :9;60( 15): 1340-8.

41. Klipstein F.A, Lindenbaum J. Folate deficiency in chronic liver disease. Blood 1965;25:443-56.

42. Latib A, Colombo A, Castriota F, et al. A Randomized Multicenter Study Comparing a Paclitaxel Drug-ElutingBalloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels: The BELLO (Balloon Elution and Late Loss Optimization) Study. J Am Coll Cardiol. 2012 : 18;60(24):2473-80.

43. Levine R.F, Spivak J.L, Meagher R.C, et al. Effect of ethanol on thrombopoiesis. Br J Haematol 1986;62(2):345-54.

44. Lip GYH: Improving stroke and thromboembolism risk stratification in chronic atrial fibrillation. E-Journal of the ESC Council for Cardiology Practice, 2010;8 (36), 9.

45. Lisman T, Caldwell S.H, Leebeek F.W, et al. Is chronic liver disease associated with a bleeding diathesis? J Thromb Haemost 2006;4(9):2059-60.

46. Lisman T, Leebeek F.W, de Groot P.G. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002;37(2):280-7.

47. Lloyd-Jones D.M, Wang T.J, Leip E.P, et al. Lifetime risk for development of atrial fibrillation: The Framingham HeartStudy. Circulation. 2004; 110(9): 1042-1046.

48. Mannucci P.M. Abnormal hemostasis tests and bleeding in chronic liver disease:are they related? No J Thromb Haemost 2006;4(4):721-3.

49. McVay P.A, Toy P.T. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94(6):747-53.

50. Mega J, Carreras ET Antithrombotic therapy: triple therapy or triple threat? Hematology Am Soc Hematol Educ Program 2012;2012:547-52.

51. Montalescot G, Hulot J-S, Collet J-P. Stent thrombosis: who's guilty? Eur Heart J 2009; 30: 2685 - 2.

52. Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis С viral infection. J Hepatol 1996;24(2): 135-40.

53. Ono S, Fujishiro M, Kodashima S et alEvaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. J Gastroenterol. 2012 Jul;47(7):770-4.

54. Orale Antikoagulation bei nicht valvul rem Vorhofflimmern. Empfehlungen zum Einsatz der neuen Antikoagulantien Dabidartan (Pradaxa) und Rivaroxaban (Xarelto). Version 1.0 September 2012. S.31 Arztneimittelkommision der deutschen rzteschaft http://www.akdae.de/Arzneimitteltherapie/TE/LF/index.html.

55. Orale Antikoagulation bei nicht valvul rem Vorhofflimmern. Empfehlungen zum Einsatz der neuen Antikoagulantien Dabidartan (Pradaxa) und Rivaroxaban (Xarelto). Version 1.0 September 2012. S.31 Arztneimittelkommision der deutschen rzteschaft http://www.akdae.de/Arzneimitteltherapie/TE/LF/index.html.

56. Schepke M Ptzsch B, Unkrig C, Sauerbruch T Endoskopie bei Patienten mit erh htem Blutungsrisiko. In: Sauerbruch T, Scheurlen Ch (Hrsg) Empfehlungen der Deutschen Gesellschaft fr Verdauungs- und Stoffwechselkrankheiten (DGVS) fr die Durchf hrung endoskopischer Untersuchungen, 2002, 3. Auflage, Demeter Verlag, Stuttgart, S. 30-40 (www.DGVS.de/Leitlinien/1.3.Blutungsrisiko.pdf.

57. Silber S, Borggrefe M, В hm M et al. Medikamente freisetzende Koronarstents(DES) und Medikamente freisetzende Ballonkatheter (DEB):_Aktualisierung des Positionspapiers der DGK. Clin Res Cardiol 2008; 97:548-563.

58. Silber S, Borggrefe M, В hm M et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents(DES). Kardiologe 2007; 2:84-111.

59. Stella PR, Belkacemi A, Dubois C, et al.A multicenter randomized comparison of drug-elutingballoon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-elutingballoon in bifurcations trial Catheter Cardiovasc Interv. 2012 ;80(7):1138-46.

60. Strauer B.E., Schellong S.M. Antithrombotische Behand-lungsstrategien. Der Internist 2011; 52(11): 1275.

61. Van de Wef F, Bax J, Betriu A et al. (2008) Management ofacutemyocardialinfarction in patientspresentingwith persistent ST-segment elevation. Eur Heart J 29:2909-2945.

62. Vernava AM 3rd, Longo WE.Complications of endoscopic polypectomy. Surg Oncol Clin N Am. 1996;5:663-673. [

63. Waye J.D. Colonoscopy. CA Cancer J Clin. 1992;42:350-365.

64. Wiviott S.D, Braunwald E, McCabe C.H et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001-2015.

65. Wiviott S.D, Braunwald E, McCabe C.H et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.

66. Yusuf S, Zhao F, Mehta S.R, Chrolavicius S, Tognoni G, Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ;345(7):494-502.

67. Zuckerman M.J, Hirota W.K, Adler D.G, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005;61:189-194.